Caricamento...
Modelling population-level impact to inform target product profiles for childhood malaria vaccines
BACKGROUND: The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5–17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot implementation program. Work is ongoing to optimise this vaccine, with higher eff...
Salvato in:
| Pubblicato in: | BMC Med |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6044028/ https://ncbi.nlm.nih.gov/pubmed/30001708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-018-1095-6 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|